缺血性心肌病的冠状动脉血运重建
缺血性心肌病患者即使接受最佳药物治疗预后仍较差,且常被排除在稳定性冠心病的血运重建随机试验之外。血运重建可能通过逆转心肌冬眠、抑制室性心律失常和预防自发性心肌梗死等机制获益。冠状动脉旁路移植术被视为一线血运重建方式,STICH 试验显示死亡率降低但需延长随访才显现,经皮冠状动脉介入治疗尚缺乏随机对照试验证据,REVIVED-BCIS2 试验已完成招募并将填补这一空白。
要点
- 缺血性心肌病患者预后差,且常被排除在血运重建随机试验之外。
- 冠状动脉旁路移植术为一线血运重建方式,STICH 试验显示死亡率降低但需延长随访才显现。
- 经皮冠状动脉介入治疗尚缺乏随机对照试验证据,REVIVED-BCIS2 试验已完成招募。
核心结论
- 缺血性心肌病患者可从血运重建中获益,冠状动脉旁路移植术为一线方式,经皮冠状动脉介入治疗证据待 REVIVED-BCIS2 试验填补。
研究设计与样本
- 本文为综述,总结缺血性心肌病患者血运重建的机制、证据与未来方向。
主要发现
- 血运重建可能通过逆转心肌冬眠、抑制室性心律失常和预防自发性心肌梗死等机制获益。
- STICH 试验显示冠状动脉旁路移植术降低死亡率,但需延长随访才显现,因手术组早期不良事件过多。
- 经皮冠状动脉介入治疗在缺血性心肌病患者中尚缺乏随机对照试验证据。
临床怎么用
- 冠状动脉旁路移植术应作为缺血性心肌病患者血运重建的首选方式。
- 经皮冠状动脉介入治疗的应用需等待 REVIVED-BCIS2 试验结果。
局限性
- 缺血性心肌病患者常被排除在稳定性冠心病的血运重建随机试验之外。
- 经皮冠状动脉介入治疗在缺血性心肌病患者中尚无随机对照试验证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Heart failure resulting from ischaemic heart disease is associated with a poor prognosis despite optimal medical treatment. Despite this, patients with ischaemic cardiomyopathy have been largely excluded from randomised trials of revascularisation in stable coronary artery disease. Revascularisation has multiple potential mechanisms of benefit, including the reversal of myocardial hibernation, suppression of ventricular arrhythmias and prevention of spontaneous myocardial infarction. Coronary artery bypass grafting is considered the first-line mode of revascularisation in these patients; however, evidence from the Surgical Treatment of Ischaemic Heart Failure (STICH) trial showed a reduction in mortality, though this only became apparent with extended follow-up due to an excess of early adverse events in the surgical arm. There is currently no randomised controlled trial evidence for percutaneous coronary intervention in patients with ischaemic cardiomyopathy; however, the REVIVED-BCIS2 trial has recently completed recruitment and will address this gap in the evidence. Future directions include (1) clinical trials of revascularisation in patients hospitalised with heart failure, (2) defining the role of viability and ischaemia testing in heart failure, (3) studies to enhance the understanding of the mechanistic effects of revascularisation and (4) generating models to refine pre- and post-revascularisation risk prediction.
引用
- Ryan M, Morgan H, Petrie MC, et al. Coronary revascularisation in patients with ischaemic cardiomyopathy. Heart. 2021. PMID: 33436491. doi:10.1136/heartjnl-2020-316856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。